Liraglutide (Victoza) Research Overview (also known as Victoza, Saxenda, NN2211, Liraglutide acetate)

By , Founder of RUO Codes · Last updated

At a glance

Liraglutide (Victoza) research overview

What Is Liraglutide (Victoza)?

Liraglutide is a synthetic, long-acting analogue of human glucagon-like peptide-1, or GLP-1, a hormone produced primarily by intestinal L cells after food intake. It has approximately 97% amino-acid sequence identity with native human GLP-1. Structural modifications, including substitution of an amino acid and attachment of a fatty-acid side chain, increase albumin binding and slow enzymatic degradation by dipeptidyl peptidase-4. These changes extend its circulating half-life to approximately 13 hours, allowing once-daily subcutaneous administration rather than the very short exposure associated with endogenous GLP-1.

Liraglutide was developed by Novo Nordisk and received United States Food and Drug Administration approval as Victoza in 2010 for improving glycemic control in adults with type 2 diabetes; pediatric use was subsequently expanded in selected age groups. The 3-mg formulation, marketed as Saxenda, was approved in 2014 as an adjunct to reduced-calorie nutrition and increased physical activity for chronic weight management in adults with obesity or overweight accompanied by weight-related health conditions. Liraglutide is related to, but pharmacokinetically different from, semaglutide: liraglutide is generally injected daily and has a half-life of about 13 hours, whereas semaglutide is formulated for weekly administration and has a half-life of approximately one week. Both activate the GLP-1 receptor, but dose, exposure profile, clinical outcomes, and tolerability are not interchangeable. Liraglutide remains important in metabolic research involving appetite regulation, beta-cell physiology, cardiovascular risk, fatty liver disease, and neurodegenerative mechanisms.

Victoza and Saxenda contain the same active molecule but are approved, labeled, and dosed for different indications. Victoza is used at doses up to 1.8 mg daily for type 2 diabetes, while Saxenda is titrated to 3 mg daily for obesity treatment. Neither product should be used as a substitute for the other without clinical supervision. The term research use may refer either to investigation of approved clinical treatment or to laboratory study of GLP-1 biology; it does not imply that unsupervised use of prescription liraglutide or nonapproved formulations is safe.

Quick Reference

Member reference tables summarize the compound's research parameters.

Sign in to view this section

Research Indications

Glycemic Control
Strong Evidence

Type 2 diabetes HbA1c reduction

Large randomized trials support clinically meaningful HbA1c reductions when liraglutide is used with diet, activity, and background glucose-lowering therapy.

Fasting and postprandial glucose

GLP-1 receptor activation enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, and slows gastric emptying.

Cardiovascular Risk Reduction
Strong Evidence

Major adverse cardiovascular events

In the LEADER cardiovascular outcomes trial, liraglutide reduced the composite risk of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in high-risk type 2 diabetes.

Cardiovascular mortality

Evidence from the outcomes trial supports a reduction in cardiovascular death among patients with established cardiovascular risk.

Body Weight and Appetite
Supported Research

Weight loss with lifestyle intervention

Liraglutide can reduce body weight through appetite and energy-intake effects; weight-focused research commonly uses the higher 3 mg liraglutide regimen marketed separately as Saxenda.

Reduced hunger and food intake

Central and gastrointestinal GLP-1 signaling is associated with increased satiety, reduced hunger, and smaller spontaneous energy intake in clinical studies.

Prediabetes and Diabetes Delay
Emerging Evidence

Delay of type 2 diabetes onset

A long-term trial in people with obesity and prediabetes found fewer diagnoses of type 2 diabetes during treatment with 3 mg liraglutide plus lifestyle intervention.

Metabolic risk-factor improvement

Changes in weight, glycemia, and some cardiometabolic measures have been observed, but applicability depends on population, dose, and concurrent lifestyle treatment.

Research Protocols

As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.

This member section describes parameters reported in the research literature.

Sign in to view this section

Peptide Interactions

This member section summarizes reported compound interactions and evidence limitations.

Sign in to view this section

Reported Research Time Points

This member section summarizes reported research time points.

Sign in to view this section

Safety Notes

Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.

This member section discusses research safety considerations and uncertainties.

Sign in to view this section

Quality Indicators

Verified Marker

Authorized presentation and traceable supply

Prefer regulator-authorized, pharmacy-dispensed pens with a verifiable national drug code or equivalent identifier, lot number, and expiration date.

Verified Marker

Clear, colorless solution

The solution should be clear and colorless. A pen containing particles, cloudiness, discoloration, leakage, or visible damage must not be used.

Verified Marker

Intact labeled pen device

The listed research text specifies inspecting for intact tamper features, readable product strength, matching lot and expiration information, and a functioning dose selector.

Acceptable Range

Documented cold-chain handling

Unopened pens are generally refrigerated; storage allowances after first use depend on the approved local product labeling. The listed research text specifies confirming temperature history when supply integrity is uncertain.

Quality Concern

Unverified compounded or gray-market material

The listed research text specifies avoiding products with no traceable pharmacy source, missing lot information, unclear concentration, broken refrigeration history, or labels that do not identify liraglutide and its approved strength.

Research Citations

Research Focus

GLP-1 receptor agonist, weight loss, type 2 diabetes, cardiovascular protection, appetite suppression, insulin secretion

Related Compounds

Browse all peptides in the Encyclopedia →